Introduction {#s1}
============

Schistosomiasis, a disease caused by parasitic trematodes of the genus *Schistosoma*, is second only to malaria as the most socioeconomically devastating parasitic disease, with an estimated 252 million people infected worldwide in 2015 ([@bib17]; [@bib42]). Larval digenean trematodes share a common feature in the use of snails (gastropod mollusks) as intermediate hosts for transmission to a vertebrate host ([@bib18]). The snail *Biomphalaria glabrata* transmits several species of trematode, including *Schistosoma mansoni*, the predominant causal species of intestinal schistosomiasis ([@bib43]). The molecular interactions between *B. glabrata* and *S. mansoni* have been studied extensively towards better understanding this essential life cycle stage of an important human parasite ([@bib2]).

Various genetically determined resistance phenotypes exist with respect to *S. mansoni* infection in *B. glabrata* ([@bib49]; [@bib50]). Some *B. glabrata* snails (such as BS-90 strain) naturally resist *S. mansoni* infection. Susceptible *B. glabrata* (such as M-line strain) can develop transient levels of acquired resistance following previous exposure to incompatible or radiation-attenuated parasites with modest cross protection to related digenean species ([@bib36]; [@bib35]; [@bib51]). Previous research has focused on identifying the mechanisms responsible for determining resistance profiles. Using in vivo and in vitro models of *B. glabrata* snails, it has been demonstrated that the killing of *S. mansoni* larvae is associated with a haemocyte-mediated cytotoxic mechanism, and passive transfer of natural resistance to *S. mansoni* has been successfully accomplished when haemocytes from a susceptible *B. glabrata* strain are incubated in cell-free haemolymph (plasma) from a resistant strain ([@bib7]; [@bib8]; [@bib24]; [@bib39]). Thus, haemocytes from resistant or susceptible *B. glabrata* strains do not appear to differ a priori in their cytotoxic capabilities, but their response requires activation by some humoral factor(s) ([@bib8]; [@bib24]; [@bib53]), for proper recognition of *S. mansoni* and enhancing haemocyte cytotoxicity ([@bib26]).

Researchers have long sought immune determinants present in resistant *B. glabrata* plasma that specifically activate haemocytes to encapsulate and destroy *S. mansoni* sporocysts. Identified in *B. glabrata*, a large family of soluble lectins termed fibrinogen-related proteins (*Bg*FREPs) attracted widespread interest because of their unique structure ([@bib1]; [@bib23]), capacity for somatic diversification ([@bib63]), and immune function ([@bib28]; [@bib30]). *Bg*FREPs are composed of a C-terminal fibrinogen (FBG) domain and either one or two N-terminal immunoglobulin superfamily (IgSF) domains linked to the FBG domain by an interceding region (ICR) ([@bib33]; [@bib62]). Numerous studies have implicated *Bg*FREP3 as playing a central role in *B. glabrata* resistance to digenetic trematodes ([@bib28]; [@bib29]; [@bib30]; [@bib38]; [@bib37]; [@bib46]). *Bg*FREP3 contains two tandem IgSF domains whereas *Bg*FREP2 has one ([@bib33]). The expression of *Bg*FREP2 in BS-90 snails is dramatically up-regulated (57-fold) after exposure to *S. mansoni*, whereas M-line snails do not feature such a drastic upregulation, thereby suggesting a role for *Bg*FREP2 in resistance ([@bib31]). Interestingly, the time course for heightened *Bg*FREP2 expression overlaps the interval within which sporocysts are encapsulated and killed, and only occurs in BS-90 haemocytes ([@bib16]; [@bib31]). Furthermore it was reported that *Bg*FREP2 is reactive with *S. mansoni* polymorphic mucins (*Sm*PoMucs) found on the tegumental surface of larval *S. mansoni* ([@bib41]).

In addition to *Bg*FREPs, other soluble immune effector factors which are involved in both the direct killing of sporocysts and preparation of haemocytes to mount a cell-mediated response have been characterized ([@bib45]). These factors include *B. glabrata* thioester-containing proteins (*Bg*TEPs) ([@bib9]; [@bib41]; [@bib47]) and Biomphalysin ([@bib20]). TEPs are key components of invertebrate and vertebrate immune responses, aiding in melanization, opsonization, and killing of invading pathogens ([@bib6]; [@bib13]; [@bib34]; [@bib45]; [@bib47]; [@bib48]; [@bib59]). *Bg*TEP was first characterized as an alpha macroglobulin proteinase inhibitor, and has recently re-emerged as a molecule of interest due to its association with *Bg*FREP2 and *Sm*PoMucs, and the capacity to bind to various invading pathogens ([@bib9]; [@bib41]; [@bib47]). Biomphalysin is a cytolytic protein in *B. glabrata* belonging to the β pore-forming toxin (β-PFT) superfamily ([@bib20]). Biomphalysin binds to the surface of *S. mansoni* sporocysts in the absence of plasma, while its cytolytic activity is drastically increased when plasma is present, suggesting that other factor(s) within the plasma may mediate the conversion of the oligomeric pre-pore to a functional pore ([@bib20]). Although the functional mechanisms of these factors are not thoroughly understood, studies suggest that these factors function as key determinants in the final outcome of *S. mansoni* challenge of *B. glabrata* ([@bib20]; [@bib41]).

While studies have implicated *Bg*FREP3 in resistance to *S. mansoni*, the underlying mechanism of *Bg*FREP3 function; how it binds to *S. mansoni* sporocyst surfaces, and then how recognition is translated into haemocyte engagement, activation, and ultimately parasite encapsulation, is still unknown ([@bib28]). Here, we report an association between *Bg*FREP3, *Bg*TEP1, Biomphalysin (UniProtKB/TrEMBL: A0A182YTN9 and A0A182YTZ4) and *Bg*FREP2 (UniProtKB/TrEMBL: A0A2C9L9F5). *Bg*FREP3 associates with *Bg*TEP1 and Biomphalysin in both M-line and BS-90 strains, but only in BS-90 strain uniquely interacts with *Bg*FREP2 and other versions of *Bg*FREP3 (a variant of *Bg*FREP3.3), providing us with an important insight into why BS-90 strain is refractory to *S. mansoni* infection. In this study, we demonstrate that *Bg*FREP3 binds to *S. mansoni* sporocysts without any other soluble plasma factors, yet binding of *Bg*FREP2 relies on *Bg*TEP1. However, *Bg*FREP3 still interacts with *Bg*TEP1 to form unique immune complexes, which significantly enhance the ability of haemocytes and plasma from *S. mansoni*-susceptible *B. glabrata* (M-line) to kill *S. mansoni* sporocysts. A more striking finding is that the combination of *Bg*FREP3, *Bg*TEP1 and *Bg*FREP2 renders M-line haemocytes capable of killing *S. mansoni* sporocysts at nearly the same level as *S. mansoni*-resistant BS-90 haemocytes. Reactive oxygen species (ROS) are shown to play an important role during this haemocyte-mediated killing of *S. mansoni* sporocysts. These results provide insight into how the numerous previously characterized immune factors known to be important in the anti-*S. mansoni* immune response to *B. glabrata* are acting in concert to defend the snail host.

Results {#s2}
=======

*Bg*FREP3 interacts with *Bg*TEP1, Biomphalysin, *Bg*FREP2 and other *Bg*FREP3 variants in snail plasma {#s2-1}
-------------------------------------------------------------------------------------------------------

To identify the factors in snail plasma which interact with *Bg*FREP3, we produced recombinant *Bg*FREP3 (r*Bg*FREP3, GenBank: AY028461.1, M-line strain) using an insect expression system ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}) and performed a series of pull-down experiments. We initiated our investigations with *Bg*FREP3 because we observed that the cell-free plasma of BS-90 snails contained more *Bg*FREP3 than does M-line snail plasma ([Figure 1B](#fig1){ref-type="fig"}). Among the proteins identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the eluent of these pull-down experiments was *Bg*TEP1 ([Figure 1C](#fig1){ref-type="fig"}). We performed four replicate r*Bg*FREP3 pull-down experiments, each yielded a band at approximately 200 kDa, which corresponded to the full-length *Bg*TEP1, which was identified from both M-line and BS-90 strains ([Figure 1C](#fig1){ref-type="fig"}). In three instances, we excised the bands from SDS-PAGE gels for mass spectrometry identification, this showed twice that *Bg*TEP1 was pulled down by r*Bg*FREP3 in M-line plasma, while this was shown once in both M-line and BS-90 plasma ([Figure 1D](#fig1){ref-type="fig"}). From the LC-MS/MS analysis we obtained a total of 17 unique peptides, 16 peptides were detected from M-line strain, four peptides were from BS-90 strain, and three peptides were present in both BS-90 and M-line strains (Table. S2 and [Figure 1D](#fig1){ref-type="fig"}). While all peptides mapped to *Bg*TEP, there was uncertainty as to which specific *Bg*TEP proteins are present. Twelve peptides mapped to *Bg*TEP (GenBank: ACL00841.1); 15 peptides mapped to *Bg*TEP1.1 (GenBank: ADE45332.1, from a Brazilian strain of *B. glabrata*), *Bg*TEP1.2 (GenBank: ADE45339.1, from a Brazilian strain of *B. glabrata*), *Bg*TEP1.3 (GenBank: ADE45340.1, from a Brazilian strain of *B. glabrata*), *Bg*TEP1.4 (GenBank: ADE45341.1, from a Brazilian strain of *B. glabrata*) and *Bg*TEP1.5 (GenBank: ADE45333.1, from a Brazilian strain of *B. glabrata*), however, there was overlap between some of these peptides, which mapped to all known *Bg*TEP sequences ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). The *Bg*TEP identified by MS here displayed a relatively large difference from *Bg*TEP (ACL00841.1), but could not be distinguished from other *Bg*TEP1 sequences ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}), so we termed it *Bg*TEP1.

![*Bg*FREP3, which had special high abundance in BS-90 plasma, interacted with *Bg*TEP1 and Biomphalysin derived from both M-line and BS-90 plasma, while uniquely associated with *Bg*FREP2 and a *Bg*FREP3 variant from BS-90 plasma.\
(**A**) Schematic diagram and Western blot analysis of recombinant proteins, the ends of which are coupled to the tags V5 and ploy-His for protein immunoassay and purification operations. The yellow star in the schematic structure of r*Bg*TEP1 represents the thioester motif. (**B**) The background expression of *Bg*FREP3 in BS-90 snail plasma was significantly higher than that in M-line plasma. The haemolymph of four snails from each M-line and BS-90 strain was independently extracted, and haemocytes were removed by centrifugation to obtain plasma samples. After the plasma of each snail was quantified, the same amount of plasma was used for SDS-PAGE electrophoresis and Western blot analysis. Anti-IgSF \#1 and anti-FBG \#1 antibodies of *Bg*FREP3 were used as primary antibodies. (**C**) The r*Bg*FREP3 associated with *Bg*TEP1 and Biomphalysin in both M-line and BS-90 plasma, but exclusively interacted with a *Bg*FREP3 variant and *Bg*FREP2 in BS-90 plasma. The eluent of r*Bg*FREP3 pull-downs was collected and separated on 6% (upper panel) and 10% (lower panel) SDS-PAGE gels before silver staining. (**E**) The r*Bg*TEP1 interacted with Biomphalysin and *Bg*FREP2 in both M-line and BS-90 plasma. The eluent of pull-down experiments with r*Bg*TEP1was separated on 10% SDS-PAGE gels. In the pull-down experiments with r*Bg*FREP3 (**C**) and r*Bg*TEP1 (**E**), cell-free plasma from M-line (green) or BS-90 (red) *B. glabrata* snails was incubated with Sf9 cell lysates expressing r*Bg*FREP3 or concentrated medium containing r*Bg*TEP1 together (interactome experiments, last two lanes) or alone (controls, first three lanes). Bands that differ between control and interactome experiments were cut, proteins submitted to tryptic digest and analyzed by LC-MS/MS for identification. In interactome experiments, bands that differ between M-line and BS-90 lanes were marked with red arrows. The results of mass spectrometry analysis are shown in the figure. Proteins (*Bg*TEP1 and Biomphalysin) represented by black font interacted with r*Bg*FREP3 in both M-line and BS-90 plasma. Proteins (*Bg*FREP2 and *Bg*FREP3.3) represented by blue font specially interacted with r*Bg*FREP3 only in BS-90. (**D, F and G**) Distribution of peptides identified by LC-MS/MS on *Bg*TEP1.5 (ADE45333.1), Biomphalysin (A0A182YTN9) and *Bg*FREP2 (AAK13550.1). The text on the panels describes the peptides identified from different Pull-down experiments, and most peptides were identified multiple times. The text with the green background describes peptides identified from the plasma of M-line strain in the r*Bg*FREP3 pull-down experiments, and corresponding the text with the red background represents the peptides from the plasma of BS-90 strain. Similarly, the text in the green frame box represents the peptides from the plasma of the M-line strain in the r*Bg*TEP1 pull-down experiments, and corresponding the text in the red frame box represents the peptides from the plasma of the BS-90 strain. The horizontal lines in panels **D**, **F** and **G** represent the full-length amino acid sequences of *Bg*TEP1.5, Biomphalysin and *Bg*FREP2. The light blue dots and dashes indicate the location of the peptides. The purple Arabic numerals represent the number of identified peptide fragments that differ from each other.\
Figure 1---source data 1.Nucleotide sequence for cloning r*Bg*FREP3.This sequence is derived from GenBank AY028461.1. There are differences in nucleotide sequence but the amino acids match 100%. The differences are due to codon-optimization for expression in insect Sf9 cells. GenBank annotations are used to locate the individual *Bg*FREP3.2 domains: underline, signal peptide; gray shading, IgSF1 domain; double underline, small connecting region; gray shading plus frame, IgSF2 domain; wavy underline, ICR; bold underline, FBG domain; delete line, termination codon.\
Figure 1---source data 2.The peptides identified by LC-MS/MS were distributed over the full-length *Bg*TEP, but could not be used to distinguish which *Bg*TEP variant was present.Peptides identified by LC-MS/MS from r*Bg*FREP3 pull-down experiments are highlighted in gray. The GenBank accession numbers of each entry are: *Bg*TEP, ACL00841.1; *Bg*TEP1.1, ADE45332.1; *Bg*TEP1.2, ADE45339.1; *Bg*TEP1.3, ADE45340.1; *Bg*TEP1.4, ADE45341.1 and *Bg*TEP1.5, ADE45333.1.\
Figure 1---source data 3.The two Biomphalysin variants (UniProtKB/TrEMBL: A0A182YTN9 and A0A182YTZ4) identified by LC-MS/MS shared high sequence identities but were different from the previously published Biomphalysin (GenBank: AGG38744.1).(**A**) Alignment analysis of AGG38744.1 and A0A182YTN9. (**B**) Alignment analysis of AGG38744.1 and A0A182YTZ4. (**C**) Multiple sequence alignment of AGG38744.1, A0A182YTN9 and A0A182YTZ4. The identified peptides in **A**, **B** and **C** are highlighted in gray. The yellow squares and red plus signs in **A** and **B** represent sites with differing amino acids. The red frame in **A**, **B** and **C** representing differences in peptide sequences that distinguish two Biomphalysin variants (A0A182YTN9 and A0A182YTZ4).\
Figure 1---source data 4.The identified protein (UniProtKB/TrEMBL: A0A2C9L9F5) represented a variant of *Bg*FREP2 members that was distinct from other *Bg*FREP members, but was indistinguishable from other *Bg*FREP2 variants.(**A**) The amino acid sequence information of protein A0A2C9L9F5 derived from the *B. glabrata* proteome database (Genome Accession: GCA_000457365). Peptides identified by LC-MS/MS are highlighted in gray. (**B**) Alignment of multiple *Bg*FREP amino acid sequences and distribution of identified peptides. Peptides identified by LC-MS/MS are highlighted in gray. The GenBank accession numbers of each entry are: *Bg*MFREP1 partial, AAK13549; *Bg*MFREP2 precursor, AAK13550; *Bg*FREP3-2 precursor, AAK28656; *Bg*MFREP4 precursor, AAK13551; *Bg*MFREP5 partial, AAK13546; *Bg*MFREP6 partial, AAK13552; *Bg*FREP7.1 precursor, AAK28657; *Bg*MFREP8 partial, AAK13553; *Bg*MFREP9 partial, AAK13554; *Bg*MFREP10 partial, AAK13555; *Bg*MFREP11 partial, AAK13556; *Bg*FREP12.1 precursor, AAO59918; *Bg*FREP12-FBG2, AAT58639; *Bg*FREP13.1 precursor, AAO59922 and *Bg*FREP14, ABO61860. (**C**) Blast analysis of protein A0A2C9L9F5 in NCBI database. The top 30 proteins with the highest scores are listed. (**D**) Multiple sequence alignment of 30 *Bg*FREP2 family proteins listed in **C**. Peptides identified by LC-MS/MS are highlighted in gray.\
Figure 1---source data 5.Alignment of multiple *Bg*FREP3 amino acid sequences and distribution of identified peptides.Peptides identified by LC-MS/MS are highlighted in gray, the overlapping region of peptides are bold underline. GenBank annotations of *Bg*FREP3.2 (AAK28656.1) are used for locate the individual *Bg*FREP3 domains: orange, signal peptide; green, IgSF1 domain; blue, small connecting region; pink, IgSF2 domain; black, ICR; red, FBG domain.](elife-51708-fig1){#fig1}

The full-length sequences of *Bg*TEP1 variants usually contain 1445 or 1446 amino acid residues ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). The peptides identified by LC-MS/MS covered 16.3% of the full-length sequence ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). The identified peptides were distributed over the full-length *Bg*TEP1, with the peptides identified from the BS-90 strain being concentrated in the N-terminal region ([Figure 1D](#fig1){ref-type="fig"}). Background transcript abundance of *Bg*TEP1 detected by qRT-PCR in M-line and BS-90 snails, suggested that there was no significant difference (p\>0.05) in baseline *Bg*TEP1 expression between the two strains ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These results indicate that the interaction of *Bg*FREP3 with *Bg*TEP1 doesn't require the involvement of any parasite components.

Recombinant *Bg*TEP1 (r*Bg*TEP1, GenBank: HM003907.1, Brazilian strain *B. glabrata*) was also used to perform a series of pull-down experiments ([Figure 1A and E](#fig1){ref-type="fig"}). Biomphalysin (UniProtKB/TrEMBL: A0A182YTN9 and A0A182YTZ4) was identified in both M-line and BS-90 plasma from r*Bg*TEP1 pull-down experiments and was also present in the pull-down studies using r*Bg*FREP3 ([Figure 1C and E](#fig1){ref-type="fig"}). Analysis suggested that Biomphalysin-A0A182YTN9 and Biomphalysin-A0A182YTZ4 amino acid sequences were 94% and 99% identical to the Biomphalysin (GenBank: AGG38744.1) previously reported ([@bib20]) ([Figure 1---source data 3A,B](#fig1sdata3){ref-type="supplementary-material"}). The 13 peptides identified by LC-MS/MS covered 28.3% of Biomphalysin (A0A182YTN9) amino acid sequence ([Figure 1F](#fig1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"} and [Figure 1---source data 3C](#fig1sdata3){ref-type="supplementary-material"}). These peptides were evenly distributed throughout the Biomphalysin-A0A182YTN9 protein ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}). The theoretical molecular weight of Biomphalysin is \~64 kDa. Peptides identified from protein pull-down that matched to Biomphalysin appeared at three different molecular weights, one at \>400 kDa ([Figure 1C](#fig1){ref-type="fig"}), the second site at roughly 60 kDa ([Figure 1C and E](#fig1){ref-type="fig"}), which is in agreement with the theoretical molecular weight, and the third at around 55 kDa ([Figure 1C](#fig1){ref-type="fig"}), which might represent the size after proteolysis ([@bib20]).

Comparing r*Bg*FREP3 pull-down results between M-line and BS-90 *B. glabrata* identified two unique proteins in the BS-90 lane ([Figure 1C](#fig1){ref-type="fig"}). One of these proteins was *Bg*FREP2 (UniProtKB/TrEMBL: A0A2C9L9F5) ([Figure 1C and E](#fig1){ref-type="fig"}, [Figure 1---source data 4A](#fig1sdata4){ref-type="supplementary-material"}). Five peptides were identified by LC-MS/MS analysis and covered 16.6% of *Bg*FREP2 precursor (GenBank: AAK13550.1) amino acid sequence and were located throughout the IgSF and FBG of the protein ([Figure 1G](#fig1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"} and [Figure 1---source data 4](#fig1sdata4){ref-type="supplementary-material"}). Three of the five identified peptides specifically belonged to *Bg*FREP2 precursor (AAK13550.1), thus, the identified *Bg*FREP2-A0A2C9L9F5 appears to represent a specific *Bg*FREP2 variant that is distinct from other *Bg*FREP members that have been published ([Figure 1---source data 4B](#fig1sdata4){ref-type="supplementary-material"}), but not distinguishable from other *Bg*FREP2 members ([Figure 1---source data 4C,D](#fig1sdata4){ref-type="supplementary-material"}). BLAST analysis indicated that *Bg*FREP2-A0A2C9L9F5 had the highest identity (96.62%) to FREP A precursor (GenBank: NP_001298226.1) ([Figure 1---source data 4C](#fig1sdata4){ref-type="supplementary-material"}), which was constitutively expressed solely in haemocytes of the BS-90 resistant strain ([@bib16]).

Only *Bg*FREP2 was identified, at \~55 kDa, from the BS-90 strain plasma when r*Bg*FREP3 was used as the bait protein in pull-down experiments ([Figure 1C](#fig1){ref-type="fig"}). This contrasted with our other data in which *Bg*FREP2 was identified from plasma of both M-line and BS-90 strains when r*Bg*TEP1was used as bait in pull-down experiments ([Figure 1E](#fig1){ref-type="fig"}). *Bg*FREP2 was identified by LC-MS/MS from two distinct molecular weight bands in the BS-90 lane of the r*Bg*FREP3 study and the r*Bg*TEP1 study. One band, at \~60 kDa also included peptides that mapped to Biomphalysin while the other band identified at \~55 kDa, contained peptides for only *Bg*FREP2 ([Figure 1C and E](#fig1){ref-type="fig"}). Thus, all of the *Bg*FREP2 peptides were identified from bands that were of greater molecular weight than the predicted *Bg*FREP2, which was \~43 kDa. However, this was consistent with the observed molecular weight of *Bg*FREP2 by [@bib41], and could be explained by post-translational modifications such as glycosylation ([@bib1]; [@bib41]; [@bib64]).

Another unique protein identified from the BS-90 lane in the r*Bg*FREP3 pull-down experiments was a variant of *Bg*FREP3 ([Figure 1C](#fig1){ref-type="fig"}). Of the nine peptides identified by LC-MS/MS, seven specifically matched *Bg*FREP3.3 (Genbank: AEO50747.1), the other two matched other members of *Bg*FREP3 family: *Bg*FREP3.3 (GenBank: AAO59915.1), *Bg*FREP3.2 (GenBank: AEO50746.1), *Bg*FREP3.2 (GenBank: AAK28656.1) and *Bg*MFREP3 (GenBank: AAK13548.1), suggesting that this protein was likely a FREP3 variant ([Figure 1---source data 5](#fig1sdata5){ref-type="supplementary-material"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). The seven peptides that specifically belonged to *Bg*FREP3.3 (AEO50747.1) covered 15.6% of the amino acid sequence length and mainly concentrated in the ICR (five peptides), and one peptide in each of the IgSF2 domain and FBG domain ([Figure 1---source data 5](#fig1sdata5){ref-type="supplementary-material"}). These results suggest that *Bg*FREP3, *Bg*TEP1, Biomphalysin and *Bg*FREP2 associate with each other in *B. glabrata* plasma, with M-line and BS-90 strains displaying differing interactomes. Our data indicates that *Bg*FREP3 specially interacts with *Bg*FREP2 and another unique *Bg*FREP3 variant only in BS-90 *B. glabrata*. These results provide us with a new perspective to explore why M-line and BS-90 strains have differing compatibility phenotypes to *S. mansoni* infection.

*Bg*FREP3 independently recognizes and binds to primary sporocysts of *S. mansoni* {#s2-2}
----------------------------------------------------------------------------------

Our data suggests a close and complex interaction between *Bg*FREP3, *Bg*TEP1, Biomphalysin and *Bg*FREP2. These factors have each independently been reported to be involved in the recognition of *S. mansoni* sporocysts ([@bib1]; [@bib20]; [@bib28]; [@bib29]; [@bib41]; [@bib47]; [@bib57]). However, only Biomphalysin is known to directly bind to the surface of *S. mansoni* sporocysts without the aid of any other plasma factors ([@bib20]). The mechanism by which *Bg*FREP3, *Bg*TEP1 and *Bg*FREP2 bind to primary sporocysts of *S. mansoni* is still not clear. To explore this issue, we produced r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 (GenBank: AY012700.1, M-line strain) to observe whether they associate with primary sporocysts of *S. mansoni* ([Figure 1A](#fig1){ref-type="fig"}). Immunocytochemistry clearly showed that r*Bg*FREP3 and combination of r*Bg*FREP3 and r*Bg*TEP1 were able to interact with the outer tegument of *S. mansoni* sporocysts ([Figure 2](#fig2){ref-type="fig"}), while r*Bg*TEP1 and r*Bg*FREP2 alone did not have such capabilities ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). However, incubation of sporocysts with pre-combined r*Bg*FREP2 and r*Bg*TEP1 yielded a signal, suggesting that these two factors required complex formation prior to being able to associate with *S. mansoni* sporocysts ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These results indicate the mechanisms by which *Bg*FREP3 and *Bg*FREP2 recognize *S. mansoni* sporocysts are different, that is, *Bg*FREP3 does not require *Bg*TEP1 in order to associate with targets on the *S. mansoni* sporocyst surface while *Bg*FREP2 relies on *Bg*TEP1 to bind to *S. mansoni* sporocysts.

![A combination of r*Bg*FREP2 + r*Bg*TEP1, and r*Bg*FREP3 in the presence and absence of r*Bg*TEP1, are capable of binding to the surface of *S. mansoni* sporocysts.\
Fixed sporocysts were incubated with a vehicle control or recombinant proteins (r*Bg*FREP3, r*Bg*FREP2, and r*Bg*TEP1 alone) and combinations of r*Bg*FREP2+r*Bg*TEP1 or r*Bg*FREP3+r*Bg*TEP, followed by immunostaining with anti-V5 primary IgG and Alexa Fluor 633 goat anti-mouse secondary antibody. White bar in the bright field column represents 25 μm.](elife-51708-fig2){#fig2}

*Bg*FREP3 and *Bg*TEP1 form an immune complex {#s2-3}
---------------------------------------------

To further investigate whether *Bg*FREP3 and *Bg*TEP1 form a complex, we carried out a set of immunoblotting experiments with recombinant proteins. As expected, r*Bg*FREP3 did form a complex with r*Bg*TEP1 ([Figure 3A](#fig3){ref-type="fig"}). The complex appeared in a region of high molecular weight (\>460 kDa), and the signal decreased gradually with the decrease of r*Bg*TEP1:r*Bg*FREP3 ratios in a dose-dependent manner ([Figure 3A](#fig3){ref-type="fig"}). As shown in [Figure 3A](#fig3){ref-type="fig"}, r*Bg*FREP3 was found as a high molecular weight multimer in a non-denatured state. The molecular weights of the r*Bg*FREP3 multimer and the r*Bg*FREP3-r*Bg*TEP1 complex were both \>460 kDa, thus, it was difficult to distinguish them using Western blot. To confirm the interaction between r*Bg*FREP3 and r*Bg*TEP1, a far-Western blotting approach, in which decreasing amounts of r*Bg*TEP1 were separated by SDS-PAGE, and transferred to a nitrocellulose membrane, and then detected by using biotinylated r*Bg*FREP3 was performed. A band was detected in the lane with 2 μg of r*Bg*TEP1, confirming the interaction between r*Bg*FREP3 and r*Bg*TEP1 ([Figure 3B](#fig3){ref-type="fig"}).

![Both r*Bg*FREP3 and r*Bg*FREP2 interacted with r*Bg*TEP1 to form complexes.\
(**A**) Purified r*Bg*TEP1 was incubated with r*Bg*FREP3 in the indicated ratios (wt/wt in µg) for 2 hr at room temperature. After the incubation, Western blot analysis was carried out under denaturing (heating with reducing agent, the right) and non-denaturing (no heating, no reducing agent, the left) conditions, respectively. (**B**) Decreasing amounts of r*Bg*TEP1 were blotted onto the membrane and then subjected to standard Western blot (the left) and far-Western blot (the right) analysis. (**C**) The interaction between r*Bg*FREP2 and r*Bg*TEP1. Western blot analysis under non-denaturing (the upper) and far-Western blot analysis (the below) was carried out, respectively. In the far-Western blot, the biotinylated r*Bg*FREP3 and r*Bg*FREP2 acts as a primary antibody and the secondary antibody is a streptavidin-HRP; the red arrow indicates the band that symbolizes the interaction between *Bg*TEP1 and r*Bg*FREP3 or r*Bg*FREP2.](elife-51708-fig3){#fig3}

*Bg*FREP2 and *Bg*TEP1 have been shown to form immune complexes with *Sm*PoMucs derived from *S. mansoni* ([@bib41]), suggesting that *Bg*FREP2 and *Bg*TEP1 associate with each other in snail plasma. To test this assumption, we performed a set of immunoblot assays using r*Bg*FREP2 and r*Bg*TEP1. The results of Western blot under non-denaturing conditions showed a band (\>460 kDa) after mixing r*Bg*FREP2 and r*Bg*TEP1 ([Figure 3C](#fig3){ref-type="fig"} upper panel). The intensity of this band decreased on the Western blot in a dose dependent manner along with the decrease of the r*Bg*TEP1:r*Bg*FREP2 ratios ([Figure 3C](#fig3){ref-type="fig"} upper panel). However, r*Bg*FREP2 did not exist as a multimer under non-denaturing conditions ([Figure 3C](#fig3){ref-type="fig"} upper panel), which was consistent with the findings of ([@bib64]). In addition, we further verified the interaction between r*Bg*FREP2 and r*Bg*TEP1 by Far-Western blot ([Figure 3C](#fig3){ref-type="fig"} lower panel).

Association of *Bg*FREP3 and *Bg*TEP1 facilitates recognition and killing of *S. mansoni* sporocysts {#s2-4}
----------------------------------------------------------------------------------------------------

*Bg*FREP3 does not rely on *Bg*TEP1 to recognize and bind to *S. mansoni*-associated proteins, but does associate with *Bg*TEP1, because of this, we hypothesize that *Bg*TEP1 plays a role in the downstream immune response triggered by *Bg*FREP3 recognition of *S. mansoni* sporocysts. We treated primary sporocysts with haemocytes or plasma from BS-90 and M-line *B. glabrata* snails with r*Bg*FREP3, r*Bg*TEP1 and a combination of the two in vitro.

Plasma (haemoglobin-low/free) from the resistant BS-90 strain of *B. glabrata* snails was naturally able to kill 67% (SEM 3.7%; n = 10) of *S. mansoni* sporocysts by 48 hr post incubation, while plasma from the susceptible M-line strain, which killed 20% (SEM 4.5%; n = 10), was not significantly more effective than the medium control in which 13% (SEM 2.1%; n = 10) were killed at 48 hr ([Figure 4A](#fig4){ref-type="fig"}). The addition of r*Bg*FREP3 (36% \[SEM 5.0%; n = 10\]) and r*Bg*TEP1 (32% \[SEM 3.3%; n = 10\]) independently did not significantly enhanced the ability of M-line plasma to kill *S. mansoni* sporocysts by 48 hr ([Figure 4A](#fig4){ref-type="fig"}). However, the combined addition of r*Bg*FREP3 and r*Bg*TEP1 significantly increased M-line-plasma-mediated killing of *S. mansoni* sporocysts by 48 hr post incubation (56% \[SEM 4.8%; n = 10\]) compared to the application of either recombinant protein alone. The combined addition of r*Bg*FREP3 and r*Bg*TEP1 rendered the capacity of M-line plasma able to kill *S. mansoni* sporocysts statistically insignificant from BS-90 plasma (p\>0.05) ([Figure 4A](#fig4){ref-type="fig"}). Recombinant proteins, in the absence of *B. glabrata* plasma, did not display any capacity to kill *S. mansoni* sporocysts ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). This suggests that r*Bg*FREP3 and r*Bg*TEP1 activate one or more factors in plasma to confer the ability to kill sporocysts. Combined with the results of our r*Bg*FREP3 and r*Bg*TEP1 pull-down experiments, we speculate that Biomphalysin plays an important role in this process. However, an alternative mechanism underpinning plasma-mediated killing may be elevated circulating levels of ROS (e.g., H~2~O~2~) naturally occurring in the plasma of BS-90 compared to M-line *B. glabrata*. To address this possibility, catalase (a ROS scavenger) was pre-incubated with BS-90 plasma and M-line plasma. Catalase did not affect the *S. mansoni* sporocyst killing capacity of BS-90 plasma nor did it influence M-line plasma incubated with r*Bg*FREP3 and r*Bg*TEP1 ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), suggesting that other factors besides ROS were activated by r*Bg*FREP3 and r*Bg*TEP1 to mediate sporocyst killing.

![Association of r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 increased the ability of M-line snails to kill *S. mansoni* sporocysts.\
Effects of r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP3-r*Bg*TEP1 complex on killing of *S. mansoni* sporocysts by M-line plasma (**A**) and haemocytes (**B**). (**C**) Before being exposed to sporocysts, M-line haemocytes were pre-incubated with r*Bg*FREP3-r*Bg*TEP1-r*Bg*FREP2 combination in presence or in absence of anti- *Bg*FREP3 antibodies (abrogation treatment). BS-90 haemocytes were incubated with anti-*Bg*FREP3 antibodies. (**D**) The effect of r*Bg*FREP2, r*Bg*TEP1 and r*Bg*FREP2-r*Bg*TEP1 complex on the destruction of sporocysts by M-line haemocytes. (**E and F**) The role of ROS in killing of *S. mansoni* sporocysts by haemocytes from *B. glabrata* snails. (**E**) The addition of ROS inhibitors NAC and DPI abolished the ability of BS-90 haemocytes to destroy sporocysts. (**F**) Killing sporocysts of M-line haemocytes rendered by r*Bg*FREP3-r*Bg*TEP1 complex was annulled by pre-incubation with ROS inhibitors NAC and DPI. Statistically significant difference symbols in **A**, **B** and **D**: asterisk (\*) represents comparison with M-line haemocytes or plasma, \*p\<0.05, \*\*p\<0.01; a represents comparison with BS-90 haemocytes or plasma, p\<0.05; b represents comparison with both single treatment (r*Bg*TEP1/r*Bg*FREP3 or r*Bg*FREP2), p\<0.05; c represents comparison with only *Bg*FREPs treatment, p\<0.05; bars represent SEM, n = 10. Statistically significant difference symbols in **C**: \# represents comparison BS-90 haemocytes with BS-90 haemocytes+anti-r*Bg*FREP3 antibodies, p\<0.05; \$ represents comparison M-line haemocytes+r*Bg*FREP3+r*Bg*FREP2+r*Bg*TEP1 with M-line haemocytes+r*Bg*FREP3+r*Bg*FREP2+r*Bg*TEP1+anti-r*Bg*FREP3 antibodies, p\<0.05; bars represent SEM, n = 10. Statistically significant difference symbols in **E** and **F** e represents comparison NAC treatment with BS-90 haemocytes or M-line haemocytes+r*Bg*FREP3+r*Bg*TEP1, p\<0.05; f represents comparison DPI treatment with BS-90 haemocytes or M-line haemocytes+r*Bg*FREP3+r*Bg*TEP1, p\<0.05; bars represent SEM, n = 6.\
Figure 4---source data 1.*S. mansoni* sprorcyst killing assay raw data.](elife-51708-fig4){#fig4}

Haemocytes derived from BS-90 strain *B. glabrata* were innately capable of destroying *S. mansoni* sporocysts, killing 88% (SEM 3.6%; n = 10) of sporocysts after 48 hr of incubation in vitro ([Figure 4B](#fig4){ref-type="fig"}). The basal ability of M-line haemocytes to kill sporocysts (13% \[SEM 3%; n = 10\]) was not significantly different from the medium-alone control (13% \[SEM 2.1%; n = 10\]), and was only slightly increased by adding r*Bg*FREP3 (24% \[SEM 3.4%; n = 10\]) at 48 hr ([Figure 4B](#fig4){ref-type="fig"}). Addition of r*Bg*TEP1 did significantly increase sporocyst killing by M-line haemocytes to 40% (SEM 3.9%; n = 10) ([Figure 4B](#fig4){ref-type="fig"}), however, this killing response was significantly enhanced to 61% (SEM 5.5%; n = 10) when r*Bg*FREP3 and r*Bg*TEP1 were incubated with M-line haemocytes together ([Figure 4B](#fig4){ref-type="fig"}). However, the combination of r*Bg*FREP3 and r*Bg*TEP1 did not convey a killing capacity to M-line snails that paralleled BS-90 haemocytes ([Figure 4B](#fig4){ref-type="fig"}). This suggests that there is yet another factor(s) affecting this process, causing haemocytes from BS-90 and M-line to differ in their ability to destroy sporocysts. In our r*Bg*FREP3 pull-down experiments, *Bg*FREP2 was one of the two proteins uniquely identified as associating with r*Bg*FREP3 in the plasma of BS-90 *B. glabrata* ([Figure 1C](#fig1){ref-type="fig"}). Incubation of r*Bg*FREP2 in combination with r*Bg*FREP3 and r*Bg*TEP1 enabled M-line haemocytes to kill *S. mansoni* sporocysts (83% \[SEM 4.8%; n = 6\]) to statistically indistinguishable (p\>0.05) levels as BS-90 haemocytes (88% \[SEM 4.7%; n = 6\]) ([Figure 4C](#fig4){ref-type="fig"}). To verify whether the r*Bg*FREP2-r*Bg*TEP1 complex dramatically enhanced the ability of M-line haemocytes to killing *S. mansoni* sporocysts above either factor independently, as did the r*Bg*FREP3-r*Bg*TEP1 complex, a similar experiment was performed, showing that r*Bg*FREP2-r*Bg*TEP1 did not play such a role ([Figure 4D](#fig4){ref-type="fig"}). Independent treatments of r*Bg*FREP2 (21% \[SEM 3.1%; n = 10\]) and r*Bg*TEP1 served as controls ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), demonstrating that *Bg*FREP2 alone did not facilitate sporocyst killing above control, whereas r*Bg*TEP1 killing (50% \[SEM 3.9%; n = 10\]) was indistinguishable (p\>0.05) from r*Bg*FREP2 and r*Bg*TEP1 combined (55% \[SEM 3.7%; n = 10\]) ([Figure 4D](#fig4){ref-type="fig"}).

These results made us speculate that *Bg*FREP3 was the determining factor controlling immune engagement with sporocysts and subsequent killing. Addition of three anti-r*Bg*FREP3 antibodies to the mixture of r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 significantly abrogated the increase in the ability of M-line haemocytes to kill sporocysts (51% \[SEM 3.1%; n = 6\] compared to 83% \[SEM 4.8%; n = 6\]) ([Figure 4C](#fig4){ref-type="fig"}). Pre-incubation of BS-90 haemocytes with the anti-r*Bg*FREP3 antibodies also significantly reduced their ability to destroy sporocysts (68% \[SEM 3.1%; n = 6\] compared to 88% \[SEM 4.7%; n = 6\]) ([Figure 4C](#fig4){ref-type="fig"}). Combined pre-immunized IgG purified from serum from the same rabbits from which the antibodies were produced was used as a negative control, demonstrating that it did not significantly affect the killing *S. mansoni* sporocysts by M-line (51% \[SEM 3%; n = 6\]) and BS-90 haemocytes (90% \[SEM 3.7%; n = 6\]) ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). These results suggest that r*Bg*FREP3 plays a central role in initiating the snail haemocyte-mediated anti-*S. mansoni* immune responses.

Finally, we hypothesize that haemocyte-mediated killing likely involves the production of ROS, which is crucial to the clearance of *S. mansoni* sporocysts ([@bib25]; [@bib26]). To investigate the role of ROS in the combined ability of r*Bg*FREP3 and r*Bg*TEP1 to enhance the ability of M-line haemocytes to kill *S. mansoni* sporocysts, ROS inhibitors N-acetyl-L-cysteine (NAC), Diphenyleneiodonium (DPI) and catalase were applied to the sporocyst killing assays. Co-incubation of BS-90 haemocytes with NAC, DPI and catalase significantly reduced their ability to kill *S. mansoni* sporocysts (45% \[SEM 5.6%; n = 6\], 57% \[SEM 4.2%; n = 6\] and 60% \[SEM 5.9%; n = 6\] respectively) compared to BS-90 haemocytes in the vehicle control (89% \[SEM 3.1%; n = 6\]) by 48 hr post incubation ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The ability of M-line haemocytes primed by the r*Bg*FREP3-r*Bg*TEP1 complex to destroy sporocysts (67% \[SEM 4.9%; n = 6\]) was also significantly abrogated by the addition of NAC (40% \[SEM 3.7%; n = 6\]) or DPI (52% \[SEM 3.1%; n = 6\]) ([Figure 4F](#fig4){ref-type="fig"}).

Discussion {#s3}
==========

In 1984, Granath and Yoshino successfully achieved passive transfer of resistance to *S. mansoni* from a refractory *B. glabrata* strain to susceptible snails via injection of cell-free haemolymph (plasma). Similar passive transfer of resistance had previously been shown using an in vitro model ([@bib7]; [@bib8]; [@bib39]). Although the oxidation of haemoglobin, which is the main protein component (97% of total protein) in *B. glabrata* plasma was later found to be toxic to *S. mansoni* sporocysts in long-term cultures ([@bib10]), and thus likely explained the passive transfer study results, further studies suggest that specific anti-parasitic factors must be present at or above a certain threshold level in *S. mansoni*-resistant snail plasma to stimulate a haemocyte-mediated destruction of sporocysts within 24--48 hr post-infection ([@bib16]). Although many important immune factors have been identified from *B. glabrata* plasma/haemocytes, such as *Bg*FREPs ([@bib1]), *Bg*TEP1 ([@bib41]), Biomphalysin ([@bib20]), Toll-like receptors (*Bg*TLRs) ([@bib44]), granulin (*Bg*GRN) ([@bib43]) and macrophage migration inhibitory factor (*Bg*MIF) ([@bib5]), it is still not known which factors ultimately underpin *B. glabrata* immunity to *S. mansoni*. Here, we provide insight into the broader interactions that take place between *B. glabrata* immune factors that leads to development of an *S. mansoni*-resistant phenotype.

Previous studies have shown that *Bg*FREPs are capable of binding to digenean trematode sporocysts and are up-regulated in response to larval infection ([@bib1]; [@bib57]; [@bib62]). *Bg*FREP3 has been shown to be a central part of the anti-*S. mansoni* immune response ([@bib28]). *Bg*FREP3 is up-regulated based on three characteristics (age, strain, and acquired resistance) of resistance of *B. glabrata* to infection with *S. mansoni* or *Echinostoma paraensei* ([@bib28]). Knock-down of *Bg*FREP3 in resistant snails using siRNA-mediated interference altered the phenotype of resistant *B. glabrata* by increasing susceptibility to *E. paraensei* infection ([@bib2]; [@bib28]). Nevertheless, we have little knowledge of the underlying mechanism by which *Bg*FREP3 interacts with other snail plasma factors in order to signal and trigger an immune response after recognizing the pathogen. In order to explore this mechanism, we conducted a series of pull-down experiments that allowed us to discover the interaction between *Bg*TEP1, Biomphalysin and *Bg*FREP2 with *Bg*FREP3 ([Figure 1](#fig1){ref-type="fig"}).

Proteomic analysis of *B. glabrata* plasma revealed that *Bg*FREP3, *Bg*TEP1 and *Bg*FREP2 display affinity for *S. mansoni* sporocyst tegumental membrane proteins ([@bib47]; [@bib57]). *Bg*TEP1 was previously reported to play a role in *Bg*FREP2 recognition of *S. mansoni* sporocyst *Sm*PoMucs, ([@bib41]; [@bib47]). Our immunofluorescence results illustrate that *Bg*FREP3 independently recognizes *S. mansoni* sporocysts, whereas *Bg*FREP2 must be involved with the participation of *Bg*TEP1 ([Figure 2](#fig2){ref-type="fig"}). We speculate that this may be due to their structural differences: *Bg*FREP3 possesses two IgSF domains, yet *Bg*FREP2 has only one; *Bg*FREP3 exists as a multimer in its natural state ([Figure 3](#fig3){ref-type="fig"}), whereas *Bg*FREP2 does not ([@bib64]). Alternatively, it is possible that the targets they recognize are different, so the immunoaffinity reactions that occur are also fundamentally different. A recent report suggests that *Bg*FREPs are likely to form multimers through the coiled-coil region of the ICR. However, this has not been supported by experimental evidence and does not completely rule out the possibility that *Bg*FREP multimer formation is mediated by the FBG or IgSF domain ([@bib22]).

*Bg*TEP1 and *Bg*FREP3 form a complex without any *S. mansoni* molecules present ([Figure 3](#fig3){ref-type="fig"}). We do not yet know exactly how *Bg*TEP1 is activated during infection. It is possible that *Bg*FREP3 is stabilizing *Bg*TEP1 like the leucine-rich repeat immune protein (LRIM)/*Anopheles Plasmodium*-responsive Leucine-rich repeat protein 1 (APL1C) complex that has been found to stabilize TEP in *Anopheles gambiae,* while also guiding it to the sporocyst's surface ([@bib19]). Additionally, our LC-MS/MS results seem to indicate that *Bg*FREP3 interacted with a full-length form of *Bg*TEP1, while previous work has only found the C-terminal portion of *Bg*TEP1 associating with *Sm*PoMucs ([@bib41]). This may indicate that once brought in association with the parasite, *Bg*TEP1 becomes cleaved/activated. *Bg*FREP3 does not require *Bg*TEP1 to recognize pathogens, this suggests *Bg*TEP1 is more likely to play a role in the downstream immune response initiated by *Bg*FREP3. Following the addition of r*Bg*FREP3 and r*Bg*TEP1, plasma demonstrated an increased capacity to kill sporocysts compared to controls ([Figure 4A](#fig4){ref-type="fig"}). Toxicity of haemoglobin oxidation to *S. mansoni* sporocysts was ruled out as a possible mechanism underpinning sporocyst killing because the *B. glabrata* plasma used in these tests had haemoglobin removed. These studies also demonstrated that recombinant *Bg*FREP3 and *Bg*TEP1 alone were not able to increase sporocyst killing, but showed that the addition of cell-free plasma with both recombinants was required, thereby implying the necessity of another factor(s). Based on our pull-down experiments, we suggest that this factor could be a Biomphalysin. Biomphalysin possesses many similarities to members of the β-PFT superfamily ([@bib32]; [@bib40]; [@bib54]; [@bib58]), and has been shown to have cytolytic activity that is mediated by a plasma factor(s) that remains to be identified ([@bib20]). Our results suggest a scenario in which *Bg*FREP3 and/or *Bg*TEP1 could be the factors associating with Biomphalysin to promote plasma-mediated sporocyst killing. *Bg*FREP3 and/or *Bg*TEP1 might activate Biomphalysin in an unknown manner, assist in the oligomerization of Biomphalysin while it forms its heptameric channel, or mediate the conversion of the oligomeric pre-pore to a functional pore. Further investigation is warranted to illustrate the role of *Bg*FREP3 and *Bg*TEP1 in the activation of Biomphalysin.

Within 2--3 hr of *S. mansoni* entry into *B. glabrata*, haemocytes surround the developing sporocysts forming multi-layered cellular capsules that kill encapsulated larvae within 24--48 hr post-infection ([@bib16]; [@bib39]). This occurs in both susceptible and resistant snail strains and has been replicated in our in vitro functional studies, where only resistant snails can eventually destroy the sporocysts without external assistance. Dinguirard et al. conducted a comparative proteomic analysis on the responses of haemocytes participating in *S. mansoni* sporocyst encapsulation reactions from susceptible and resistant *B. glabrata* strains, showing a striking differences in proteins expressed, with susceptible snail haemocytes exhibiting extensive downregulation of protein expression and a lower level of constitutively expressed proteins involved immunity (e.g., *Bg*FREP2) and ROS production compared to resistant snails ([@bib16]). This could explain why BS-90 haemocytes alone can kill *S. mansoni* sporocysts under normal in vivo conditions. After challenge, the transcript abundance of numerous *Bg*FREPs increases by 3-fold or greater in BS-90 compared to M-line *B. glabrata* ([@bib1]). Noteworthy in the context of our current study is that following challenge BS-90 snails with *S. mansoni*, transcript abundance for *Bg*FREP2 increases over 50-fold by 1 day post-exposure ([@bib16]; [@bib31]), *Bg*FREP3 increases around 4-fold by 1 day post-exposure ([@bib28]), and *Bg*TEP1 which increases by 2- to 3.5-fold from 6 to 24 hr post-exposure ([@bib47]). These dramatic increases in the abundance of immune-relevant transcripts occurring over the first 12--24 hr post exposure to *S. mansoni* sporocysts in BS-90 snails aligns closely with our results that demonstrate sporocyst killing by BS-90 haemocytes rapidly increases after 12 hr post-exposure ([Figure 4](#fig4){ref-type="fig"}).

Numerous studies have demonstrated the production of ROS by haemocytes in *B. glabrata*, especially H~2~O~2~, which plays a vital role in anti-schistosome defense ([@bib20]; [@bib25]; [@bib26]). Haemocytes from *S. mansoni*-resistant snails produce significantly more ROS than susceptible snails ([@bib11]; [@bib12]; [@bib21]). In our study, ROS was critical in BS-90 haemocyte-mediated *S. mansoni* sporocyst killing, as this ability was significantly reduced after pre-incubation with the ROS inhibitors NAC and DPI ([Figure 4E](#fig4){ref-type="fig"}). However, according to the phenomenon of passively transferred resistance, the cytotoxic potential of susceptible haemocytes may not be fundamentally different from resistant snails ([@bib24]). We infer that M-line plasma may lack some factors or may not achieve sufficient thresholds of certain factors to stimulate haemocytes to produce ROS. It is also possible that M-line haemocytes are lacking specific receptors to receive signals that upregulate ROS to effective levels able to kill *S. mansoni* sporocysts. Previously, our team identified a toll-like receptor (*Bg*TLR) from haemocyte surface of *B. glabrata* snails, which differed in abundance between M-line and BS-90 strains ([@bib44]). It has been repeatedly demonstrated in other organisms that activation of Toll-like receptors is associated with increased intracellular ROS ([@bib4]; [@bib52]; [@bib55]).

Our results indicate that the *Bg*FREP3-*Bg*TEP1 complex plays a role in raising ROS levels in M-line haemocytes ([Figure 4F](#fig4){ref-type="fig"}). We found that BS-90 haemolymph contains more *Bg*FREP3 protein than M-line ([Figure 1B](#fig1){ref-type="fig"}). Moreover, the BS-90 haemocytes significantly increased the expression level of *Bg*FREP2 during encapsulating *S. mansoni* sporocysts compared with susceptible snail haemocytes ([@bib16]). These suggest that *Bg*FREP3 and *Bg*FREP2 may play a crucial role in inducing haemocytes which take part in encapsulating sporocysts to generate ROS. We suppose that *Bg*TEP1 also plays an opsonin role in the *B. glabrata* snail haemolymph, which interacts with molecules on the surface of haemocytes, thereby promoting the phagocytosis of pathogens.

Our data suggests that there are fundamental differences between the *Bg*FREP3-mediated immune response between BS-90 and M-line *B. glabrata*. Protein Pull-down experiments yielded two obvious and unique protein bands that were present in BS-90 but not M-line pull-downs. We identified the bands to be a variant of *Bg*FREP3.3 and *Bg*FREP2 ([Figure 1C](#fig1){ref-type="fig"}), showing different immune factor interactomes between different strains. This suggests that *Bg*FREP3 variants and *Bg*FREP2 in BS-90 plasma are more prone to r*Bg*FREP3 binding, and the combination of different versions of *Bg*FREPs seems to play an important and unknown role in snail resistance. Both *Bg*FREP2 and *Bg*FREP3 are characterized by high diversity, our results imply that the versions of *Bg*FREP2 and *Bg*FREP3 in the two snail strains are different. After exposure to *S. mansoni*, the expression of *Bg*FREP2 in resistant snails is superior to that of susceptible snails ([@bib16]; [@bib23]; [@bib31]). This again suggests that *Bg*FREP2 is important in determining the outcome of the compatibility of *B. glabrata* against *S. mansoni*. Our study implies that *Bg*FREP3 seems to play an 'all or none' switching effect in determining *B.glabrata-S. mansoni* compatibility, while *Bg*FREP2 seems to play an additive role.

It has been decades since the discovery and initial characterization of *Bg*FREPs in the *B. glabrata* immune response to *S. mansoni*. While numerous studies since have implicated *Bg*FREP3 and *Bg*FREP2 along with a suite of other immune factors, as being important elements of the snail immune response to *S. mansoni*, how the response is coordinated has remained elusive. Our study presents a model in which many of the known determinants of snail resistance to *S. mansoni* work in concert to protect the snail host against infection. We map a mechanism for the interaction of *Bg*FREP3, *Bg*TEP1, *Bg*FREP2 and Biomphalysin with *S. mansoni* sporocysts in *B. glabrata* snail haemolymph that ultimately leads to sporocyst killing ([Figure 5](#fig5){ref-type="fig"}). Central to this response is *Bg*FREP3, which is able to recruit unique representatives of both *Bg*FREP2 and *Bg*FREP3 in *S. mansoni*-resistant BS-90 *B. glabrata*. With this new-found understanding of the *B. glabrata* immune response comes the ability to now undertake comprehensive assessments of how modifications to both the snail host and the parasite influence the underpinning immunological drivers of compatibility in this important model for studying human schistosomes.

![Interaction of *Bg*FREP3, *Bg*FREP2, *Bg*TEP1 and Biomphalysin in *B. glabrata* snail haemolymph and possible functional mechanisms against *S. mansoni* infection.\
This figure is a schematic drawing based on the results of previous studies and our work. In the absence of *S. mansoni* invasion (blue background area), both M-line and BS-90 *B. glabrata* snail hemolymphs contain *Bg*FREPs, *Bg*TEP1 and Biomphalysin and other immune factors. Upon *S. mansoni* infection, BS-90 strain (red background area) and M-line (green background area) strains demonstrate different protein interaction repertoires (red dotted frame in BS-90, green dotted frame in M-line). According to our pull-down results, *Bg*FREP3 in BS-90 plasma specifically interacts with *Bg*FREP2 and other versions of *Bg*FREP3 (blue horizontal one-way or two-way arrows). In addition, compared with the M-line strain, the BS-90 strain has more haemocytes (immune effector cells) in the snail haemolymph, and *Bg*FREP3, *Bg*FREP2, and *Bg*TEP1 are all up-regulated (red upward arrow). The more complex interactome of immune factors in BS-90 plasma results in higher levels of ROS (with cytotoxic activity) secreted by haemocytes. In conclusion, different coordination of humoral immune factors between BS-90 and M-line strains aids in dictating compatibility to *S. mansoni* infection.](elife-51708-fig5){#fig5}

Materials and methods {#s4}
=====================

Live material and experimental treatments {#s4-1}
-----------------------------------------

M-line and BS-90 strain *B. glabrata* snails were used in this study. M-line and BS-90 strain *B. glabrata* snails, and *S. mansoni* were maintained at the University of Alberta as described previously ([@bib43]). NMRI strain of *S. mansoni* was obtained from infected Swiss-Webster mice provided by the NIH/NIAID Schistosomiasis Resource Center at the Biomedical Research Institute ([@bib15]). All animal work observed ethical requirements and was approved by the Canadian Council of Animal Care and Use Committee (Biosciences) for the University of Alberta (AUP00000057).

Recombinant *Bg*FREP3, *Bg*TEP1 and *Bg*FREP2 Synthesis and Purification {#s4-2}
------------------------------------------------------------------------

Recombinant *Bg*FREP3 (r*Bg*FREP3, derived from GenBank: AY028461.1 sequence information from M-line strain, Synthesized by GenScript), *Bg*TEP1 (r*Bg*TEP1, GenBank: HM003907.1, sequence information from Brazil strain, isolated from M-line strain) and *Bg*FREP2 (r*Bg*FREP2, GenBank: AY012700.1, sequence information from M-line strain, isolated from M-line strain) were generated by using the Gateway cloning system according to the manufacturer's instructions (Life Technologies) as previously described ([@bib27]; [@bib43]; [@bib46]; [@bib44]), with primer information as shown in Table. S1 and Sf9 cell codon-optimized *Bg*FREP3 gene sequence information as shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. Briefly, the coding regions of *Bg*FREP3, *Bg*TEP1 and *Bg*FREP2 were amplified with Phusion high-fidelity DNA polymerase from targeted DNA templates in pUC57 plasmids (synthesized by GenScript) or cDNA generated by reverse transcription of mRNA derived from M-line strain. Blunt-end PCR products were cloned into the pENTR/D-TOPO vectors to generate entry clones. Plasmids from these entry clones were extracted and cloned into pIB/V5-His-DEST vectors in a Clonase recombination reaction to produce the expression clones. Recombinant plasmids were extracted from the expression clones and then transfected into Sf9 insect cells using Cellfectin reagent (Life Technologies). Cells that survived the screening of the antibiotic blasticidin (Thermo Fisher Scientific) were collected and lysed. Protein expression of r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 were detected by Western blot using monoclonal antibody against the V5 tag (Thermo Fisher Scientific) on the recombinant proteins.

Sf9 cells stably expressing recombinant r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 were selected, some of them were frozen as a seed stock and the rest were maintained in a medium containing blasticidin. Cultures of Sf9 cells expressing recombinant proteins were scaled up, and the pellet (containing r*Bg*FREP3) or the medium (containing secreted r*Bg*TEP1 and r*Bg*FREP2) was collected. Recombinant proteins were purified from the cell pellet lysate or the culture medium with HisTrap FF (GE Healthcare) columns using fast protein liquid chromatography (ÄKTA Pure, GE Healthcare). Purified r*Bg*FREP3, r*Bg*TEP1 and r*Bg*FREP2 were dialyzed against PBS buffer twice for 2 hr each and then once overnight using Slide-A-Lyzer dialysis kit (Thermo Scientific).

Preparation of *B. glabrata* plasma and pull-down experiment {#s4-3}
------------------------------------------------------------

Haemolymph was obtained from M-line and BS-90 strain *B. glabrata* snails by the head-foot retraction method ([@bib43]). Upon collection, haemolymph from \~5 snails of each strain (8--12 mm in diameter) was immediately placed in 1.5 mL tubes on ice, EDTA was added to a final concentration of 0.5 mM. Samples were centrifuged twice at 20,000 × g for 15 min and the cell-free fraction was collected. The 4 M Imidazole Stock Solution was added to a final concentration of 10 mM imidazole. Plasma samples were used immediately for subsequent pull-down experiment.

Pull-down assays were conducted by using Pull-Down PolyHis Protein:Protein Interaction Kit (Thermo Scientific) according to the manufacturer's instructions with some modifications. Briefly, first we prepared the 'bait' proteins, r*Bg*FREP3 and r*Bg*TEP1, from previously purified proteins or Sf9 cell lysate expressing r*Bg*FREP3 or concentrated medium containing r*Bg*TEP1. We then loaded the HisPur Cobalt Resin equilibrated for at least 30 min at room temperature onto the column according to the kit instructions. The prepared polyhistidine-tagged r*Bg*FREP3 and r*Bg*TEP1 was immobilized on the columns after five times washing with wash solution \[1:1 of Tris-buffered saline (TBS) solution: Pierce Lysis Buffer containing 10 mM imidazole\]. For cell lysates or concentrated medium containing r*Bg*FREP3 and r*Bg*TEP1, protein expression was previously analyzed by SDS-PAGE and Western blot, and 800 μL was added; for purified r*Bg*FREP3, at least 150 µg (about 500 μL) was added. After incubation for 2 hr at room temperature or overnight at 4°C, the columns were washed 5--8 times with wash solution and then 800 µL of prepared plasma (prey) containing 10 mM imidazole was added to the columns. The columns were incubated at 4°C for overnight with gentle rocking motion every few hours. After that, the columns were washed 5--8 times with the wash solution, and then eluent (washing solution containing 290 mM imidazole) was added and incubated at room temperature for 30 min with gentle rocking on a rotating platform.

The eluent collected by centrifugation was heat-treated in a Laemmli loading buffer containing a reducing agent (β-mercaptoethanol) followed by SDS-PAGE analysis and silver staining (Pierce Silver Stain for Mass Spectrometry, Thermo Scientific) was performed according to the manufacturer\'s instructions. After silver staining, we excised the desired bands for LC-MS/MS to identify the proteins.

Mass spectrometry analysis {#s4-4}
--------------------------

Mass spectrometry and protein identification was completed by Alberta Proteomics and Mass Spectrometry Facility at University of Alberta. In-gel trypsin digestion was performed on the samples. Briefly, the excised gel bands were reduced (10 mM mercaptoethanol in 100 mM bicarbonate) and alkylated (55 mM iodoacetamide in 100 mM bicarbonate). After dehydration enough trypsin (6 ng/μL, Promega Sequencing grade) was added to just cover the gel pieces and the digestion was allowed to proceed overnight (\~16 hr) at room temperature. Tryptic peptides were first extracted from the gel using 97% water/2% acetonitrile/1% formic acid followed by a second extraction using 50% of the first extraction buffer and 50% acetonitrile.

The digested samples containing tryptic peptides were resolved and ionized by using nanoflow HPLC (Easy-nLC II, Thermo Scientific) coupled to an LTQ Orbitrap XL hybrid mass spectrometer (Thermo Scientific). Nanoflow chromatography and electrospray ionization were accomplished by using a PicoFrit fused silica capillary column (ProteoPepII, C18) with 100 μm inner diameter (300 Å, 5 μm, New Objective). The mass spectrometer was operated in data-dependent acquisition mode, recording high-accuracy and high-resolution survey Orbitrap spectra using external mass calibration, with a resolution of 30,000 and m/z range of 400--2000. The fourteen most intense multiply charged ions were sequentially fragmented by using collision induced dissociation, and spectra of their fragments were recorded in the linear ion trap; after two fragmentations all precursors selected for dissociation were dynamically excluded for 60 s. Data was processed using Proteome Discoverer 1.4 (Thermo Scientific) and a *B. glabrata* proteome database (UniProt) was searched using SEQUEST (Thermo Scientific). The proteome database was a genome assembly (Genome Accession: GCA_000457365) ([@bib3]) , with download link <https://www.uniprot.org/proteomes/UP000076420>. Search parameters included a precursor mass tolerance of 10 ppm and a fragment mass tolerance of 0.8 Da. Peptides were searched with carbamidomethyl cysteine as a static modification and oxidized methionine and deamidated glutamine and asparagine as dynamic modifications.

Sporocyst transformations of *S. mansoni* and immunofluorescence staining {#s4-5}
-------------------------------------------------------------------------

Miracidia were obtained from eggs isolated from the livers of mice infected with *S. mansoni* (NMRI) as described previously ([@bib27]). Briefly, newly hatched miracidia were collected for cultivation in Chernin's Balanced Salt Solution (CBSS) ([@bib14]) containing 1 g/L each of glucose and trehalose as well as 1% pen-strep antibiotics (Life Technologies). After cultivation for 24 hr at 26°C under normoxic conditions, most miracidia transformed to primary sporocysts. These experiments were divided into two different treatment methodologies, and carried out in parallel. One treatment method was the interaction of fixed sporocysts with recombinant proteins. In this method, sporocysts were washed five times with snail PBS (sPBS) ([@bib60]), grouped and transferred to 15 mL centrifuge tubes (Corning). All in-tube washes were performed by centrifugation for 2 min at 300 × g. Primary sporocysts were fixed with 2% paraformaldehyde/sPBS (pH 7.2) at 4°C overnight, followed by five washes with sPBS and 1 hr incubation in 5% BSA/0.02% azide/sPBS (blocking buffer) at room temperature. Sporocysts were then incubated with r*Bg*FREP3 (450 ng/μL), r*Bg*TEP1 (18 ng/μL) and r*Bg*FREP2 (70 ng/μL) in blocking buffer overnight at 4°C; while control groups were incubated in blocking buffer without recombinant proteins.

In the other treatment method, live primary sporocysts were collected and grouped, washed three times with CBSS, and directly incubated with recombinant proteins (concentrations the same as in the fixed treatment method) in a 26°C incubator. Sporocysts were then washed, fixed, washed, and blocked, as per the same steps as the previous treatment method.

From then on, sporocysts from both fixed and alive treatment methods were washed five times with 1% BSA/sPBS, sporocysts and then treated with anti-V5 antibody (Life Technologies) diluted 1:400 in blocking buffer. Following primary antibody treatment, sporocysts were washed five times with 1% BSA/sPBS and incubated with a solution containing 7.5 U/mL Alexa Fluor 488 phalloidin (Invitrogen) and 4 µg/mL Alexa Fluor 633 goat anti-mouse secondary antibody (Invitrogen) in blocking buffer overnight at 4°C. Finally, sporocysts were washed five times with 1% BSA/sPBS, given 25 μL of DAPI, incubated for 5 min at room temperature, and transferred into glass bottom microwell dishes (MatTeK, USA). Sporocysts were imaged using an Leica TCS SP5 laser scanning confocal microscope and analyzed using ImageJ (NIH) and Photoshop CS4 (Adobe Systems Inc, USA).

Anti- *Bg*FREP3 polyclonal antibody generation and validation {#s4-6}
-------------------------------------------------------------

The IgSF1 and FBG domains of *Bg*FREP3 (AAK28656.1) were screened for regions of presumed antigenicity using the Optimum Antigen design tool (GenScript). Three polyclonal antibodies were generated specific for different peptides (14--15 amino acids long,\~4.4 kDa) targeting each domain. The information of these peptides is: anti-IgSF \#1: CSFKKDDLSDSKQRS; anti-IgSF \#2: CHNKYSEGRIDKSSN; anti-IgSF \#3: CNINKDLDFKEQNIT; anti-FBG \#1: TTFDRDNDEYSYNC; anti-FBG \#2: GWKEYRDGFGDYNIC and anti-FBG \#3: CLNGKWGSSDFAKGV. Peptides were synthesized by GenScript and used to immunize rabbits. Rabbits received a primary immunization and two secondary boosts at 2 and 5 weeks. One week after the second boost, rabbits were exsanguinated and the serum IgG was affinity-purified using protein A/G affinity column. These were further purified using affinity resin conjugated with the immunization peptides. The anti-*Bg*FREP3 antibodies used in this study were effective for Western blot detections at a concentration of 1:1000.

The purified antibodies were supplied by GenScript along with synthesized peptides and pre-immune serum. Specificity of the antibodies was tested against the respective peptides as well as snail plasma and haemocyte lysates. Dot blots were initially used to determine whether the antibodies recognized their peptides as well as the specificity of the recognition. Briefly, 2 µL of each supplied peptide was slowly pipetted in one spot on a nitrocellulose membrane that was divided into a grid with a pencil. The deposited peptides were dried at room temperature for about 10 min, creating a spot of approximately 2--3 mm. The membrane was then incubated in blocking buffer and processed using the same procedure described for Western blot following sample transfer to nitrocellulose membranes. In order to determine that the peptides were not being recognized by any pre-immune serum components, the above procedure was followed exactly with the exception that the respective pre-immune sera were used for the primary incubations in place of antibodies.

Western and far-Western blot analysis {#s4-7}
-------------------------------------

To test whether r*Bg*TEP1 complexes with r*Bg*FREP3 and r*Bg*FREP2, purified r*Bg*TEP1 was incubated with r*Bg*FREP3 or r*Bg*FREP2 in the following ratios (wt/wt in µg): 1:1, 1:0.75, 1:0.5, and 1:0.25 in 1.5 mL tubes for 2 hr at room temperature on a Labquake shaker (ThermoFisher Scientific) to allow potential complexes to form. After the incubation, samples were subjected to Western blot detection under denaturing (Laemmli protein loading buffer with β-mercaptoethanol and heated at 95°C for 10 min) and non-denaturing (no β-mercaptoethanol nor heating) conditions, respectively.

The Western blot experiment process was as described previously ([@bib46]). Samples were loaded on 6--14% (vol/vol) SDS-PAGE gels and run on the Mini PROTEAN Tetra system (Bio-Rad) at 150 V for 1.5--2 hr. Samples were then transferred for 1.5 hr onto 0.45 μm supported nitrocellulose membranes (Bio-Rad). Blocking was done for 1 hr at room temperature in 5% (wt/vol) skimmed milk or bovine serum albumin (BSA) prepared in TBS solution plus 0.1% Tween-20 (TBS-T buffer) before staining for 1 hr in anti-V5 mouse primary antibody at a dilution of 1:5000 in blocking buffer. Membranes were washed in TBS-T buffer for 10 min, then twice for 5 min each and once in TBS solution for 5 min. Membranes were then incubated for 1 hr in HRP-conjugated goat anti-mouse antibody diluted 1:5000 in blocking buffer followed by a wash step as described above. Finally, the blot was developed by incubating the membranes in SuperSignal West Dura Extended Duration substrate (Thermo Scientific). Chemiluminescent signals were acquired on the ImageQuant LAS 4000 machine (GE Healthcare).

To detect the *Bg*FREP3 background expression in the *B. glabrata* snail plasma, the haemolymph of four snails was obtained from each of M-line and BS-90 strain *B. glabrata* snails. The haemolymph from each snail was diluted twice with sPBS buffer (containing 0.5 mM EDTA). Samples were centrifuged at 20,000 × g for 5 min and the supernatant (cell-free plasma) was transferred into new 1.5 mL tubes. After being centrifuged at 20,000 × g for 5 min again, the supernatant was collected and used for quantification. Samples (330 μg/well) were used for subsequent Western blot analysis. The primary antibodies were polyclonal antibodies raised in rabbits against the IgSF and FBG domains of r*Bg*FREP3 (1:500 dilution) and the secondary antibody was a HRP-conjugated goat anti-rabbit IgG (1:5000 dilution).

Far-Western blotting is used to probe a membrane containing transferred protein with another protein to detect specific protein-protein interactions ([@bib56]). In our study, we detected r*Bg*TEP1 ('prey' protein) that were separated by SDS-PAGE and transferred onto a nitrocellulose membrane before being detected by biotinylated r*Bg*FREP3 and r*Bg*FREP2 ('bait' or 'probe' proteins) and a streptavidin-HRP chemiluminescent detection system. If r*Bg*TEP1 forms a complex with r*Bg*FREP3 or r*Bg*FREP2, r*Bg*FREP3 would be detected on spots in the membrane where r*Bg*TEP1 was located. First, r*Bg*FREP3 and r*Bg*FREP2 was biotinylated with EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) according to the manufacturer\'s instructions. Gradually decreasing amounts (2.0, 1.3, 0.6 and 0 µg) of r*Bg*FREP1 were separated by SDS-PAGE, and transferred to a membrane, as in a standard Western blot. Recombinant *Bg*TEP1 in the membrane was then denatured and renatured as described previously ([@bib56]). The membrane was then blocked and probed with biotinylated r*Bg*FREP3 or r*Bg*FREP2. After washing as described above in a standard Western blot, the membrane was incubated with streptavidin-HRP diluted 1:100,000 in blocking buffer at room temperature for 1 hr. Chemiluminescent signals were detected using the ImageQuant LAS 4000 machine (GE Healthcare).

Quantitative real-time PCR analysis of *Bg*TEP1 expression {#s4-8}
----------------------------------------------------------

A TRIzol reagent was utilized to extract total RNA from five whole unchallenged snails from each strain independently, after which RNA was purified using a PureLink RNA mini kit (Life Technologies). A NanoVue spectrophotometer (ThermoFisher Scientific) was used to determine RNA concentration, and first-strand cDNA synthesis using the qScript cDNA synthesis kit (Quanta Biosciences) was performed using 1 μg of RNA template. The cDNA was diluted fivefold, and 5 µL was used as template in RT-PCR using primers ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) specific for *Bg*TEP1 and *B. glabrata* β-actin (*Bg*Actin) in a SYBR Green detection system (PerfeCTa SYBR Green FastMix; Quanta Biosciences). All RT-PCRs were performed on a QuantStudio 3 PCR system (Applied Biosystems) using the following thermocycling conditions: initial hold at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, with data collection every cycle. Specificity for the gene specific primers RT-PCR was confirmed by continuous melt curve analysis.

In vitro S. mansoni sporocyst killing assays {#s4-9}
--------------------------------------------

Haemolymph from 25 M-line or BS-90 strain *B. glabrata,* sterilized as reported in [@bib26], was pooled into 1.5 mL tubes and kept on ice. Haemocytes were isolated from plasma by centrifugation at 70 × g for 10 min at 4°C followed by aspiration of the cell free plasma, which was kept for assessment of plasma-mediated killing of sporocysts. Haemocytes were resuspended in modified *Bg*e-cell medium (m*Bg*e) medium \[22% Schneider's *Drosophila* medium (Thermo Scientific), 7 mM D-glucose, 24 mM NaCl, and 20 mg/mL gentamicin at pH 7.4\] and washed three times following the same centrifugation protocol. Haemocytes were then resuspended to a final concentration of 50 cells/µL in m*Bg*e medium and 200 µL of this suspension was added to the wells of a 96-well tissue culture plate pre-treated with poly-L-lysine that contained 10 *s. mansoni* sporocysts that were transformed using previously published protocols ([@bib27]). Treatment consisted of 200 pM of each recombinant protein (*Bg*FREP3, *Bg*TEP1, *Bg*FREP2). Three anti-*Bg*FREP3 antibodies (anti-IgSF \#1 and \#3, anti-FBG \#1) that were generated to peptides within the IgSF and FBG domains were used as a cocktail (combined concentration of 2.5 mg/mL) were used the antibody blocking assays. Sporocyst viability was assessed using the protocol published by [@bib26]. Briefly, Propidium iodide (Millipore Sigma), was added to each well to a final concentration of 10 µg/mL. Sporocyst viability was assessed using a fluorescent inverted microscope (Zeiss) starting at 3 hr post incubation with haemocytes/plasma and then measured again at 6, 12, 24, 36 and 48 hr post incubation. Sporocyst death was determined by propidium iodide-staining of the nuclei of the sporocyst. Any sporocyst deemed dead, was left in the well until the end of the time-course so that the experimental conditions were not disturbed differentially in wells where sporocyst mortality was more frequent.

Cell-free plasma from M-line and BS-90 snails was ultracentrifuged at 30,000 rpm for 3 hr at 4°C to remove haemoglobin, which is known to have a toxic effect on sporocysts ([@bib10]). Haemoglobin removal using ultracentrifugation has been shown to lead to no qualitative differences in plasma protein composition other than the depletion of haemoglobin ([@bib61]). Ultracentrifuged plasma was mixed 50:50 with m*Bg*e medium at room temperature and then incubated with 10 *s. mansoni* sporocysts according to the protocol outlined above.

Assessment of reactive oxygen species production by haemocytes in vitro {#s4-10}
-----------------------------------------------------------------------

To assess the role that ROS had on sporocyst killing by haemocytes the above haemocyte in vitro killing assays were repeated with addition of three well characterized inhibitors of ROS; diphenyleneiodonium chloride (DPI) and N-acetyl-L-cysteine (NAC) and catalase. All ROS inhibitors (DPI at a final concentration of 150 nM, NAC at a final concentration of 1 mM and a working concentration of 14000 units of catalase/mL) were incubated along with haemocytes (and plasma in the case of catalase) and *S. mansoni* sporocysts as described above in the haemocyte-based sporocyst killing assay.

Bioinformatic and statistical analysis {#s4-11}
--------------------------------------

We used Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo/>) to align the amino acid sequences for *Bg*TEPs, Biomphalysins and *Bg*FREPs which acquired from GenBank \[National Center for Biotechnology Information (NCBI)\]. The alignment files were downloaded and visually inspected for obvious inaccuracies, modified if need be, and then annotated based on information provided by NCBI. To show the distribution of the identified peptides over a full length sequence, the amino acid sequences of *Bg*TEP1.5 (ADE45333.1), Biomphalysin (A0A182YTN9) and *Bg*MFREP2 (AAK13550.1) were imported into Vector NTI Advance 11.5 (Thermo Fisher Scientific) and the identified peptides were annotated. Images produced by Vector NTI software were saved by FSCapture and further processed with FSCapture and Adobe Photoshop CS4. To determine significant differences in sporocysts killing assays, one-way ANOVA with Tukey's post hoc tests were performed using GraphPad Prism version 6.0 f for Mac OS X (GraphPad; [www.graphpad.com](http://www.graphpad.com)). Statistical significance threshold was set at p≤0.05.
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**Acceptance summary:**

Schistosomiasis, a disease caused by parasitic trematodes of the genus *Schistosoma*, is the second-most socioeconomically devastating parasitic disease. *Schistosoma* use snails as intermediate hosts for transmission to a vertebrate host. The molecular interactions between the snail (*Biomphalaria glabrata*) and *Schistosoma (Schistosoma mansoni*) have been studied extensively towards better understanding this essential life cycle stage of an important human parasite. Some B. glabrata snails are naturally resistant to *Schistosoma* infection while other are susceptible. Researchers have long sought immune determinants present in resistant snail that specifically activate haemocytes to encapsulate and destroy *Schistosoma*. This led to the identification of soluble lectins termed fibrinogen-related proteins (*Bg*FREPs). This article describes the underlying mechanism of *Bg*FREP function reporting how it binds to Schistosoma *mansoni* sporocyst surfaces, and then how recognition is translated into haemocyte engagement, activation, and ultimately parasite encapsulation. Collectively, it provides insight into how numerous previously characterized immune factors known to be important in the anti-*Schistosoma* immune response act in concert to defend the snail host. This an important contribution in the fields on invertebrate immunity and parasitology.

**Decision letter after peer review:**

Thank you for submitting your article \"Coordination of humoral immune factors dictates compatibility between \< *Schistosoma mansoni* and *Biomphalaria glabrata*\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Coen Adema (Reviewer \#2); Tim Yoshino (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Although a diversity of soluble hemolymph proteins has been previously associated with immune resistance to larval schistosome infection in inbred strains of the snail *Biomphalaria glabrata*, the mechanism(s) mediating larval recognition and/or killing in model *B. glabrata/S. mansoni* systems has not been defined. Li et al. present evidence that differing molecular interaction of four of the major immune proteins (Frep3, Tep1, Frep2 and Biomphalysin) can account for or explain the infectivity phenotypes exhibited by susceptible (M-line) and resistant (BS-90) *B. glabrata* strains. This was accomplished by generating recombinant Frep3, Tep1 and Frep2 proteins and specific anti-Frep3 antisera, and incorporating these in plasma pull-down assays, sporocyst binding assays, Western and far-Western blot analyses and in vitro cytotoxicity inhibition assays. All experiments appeared to be well-designed and appropriately controlled, and overall results generally support their conclusion that interactions between Frep3, in association with Tep1 and Frep2, and host hemocytes account for the different compatibility phenotypes exhibited in this model system. However, there are several points that need addressing that could result in altered conclusions or significant clarifications.

Essential revisions:

1\) Physical evidence that rFrep3 alone, but not rFrep2 or rTep1 alone, can bind to sporocysts is provided by ICC using fixed parasites. Assuming, as stated, that recomb. proteins bind to the outer tegumental of larvae, the localization pattern of Frep3 and Frep2/Tep1 binding do not appear to reflect such a surface binding pattern. This raises the question regarding the specificity of Frep2/3/Tep reactivity with the tegument of living sporocysts, which is at the center of this paper. Performing similar ICC experiments, initially treating live sporocysts to recombinant proteins (suggest shorter exposure times of 4-6 hrs), washing and then fixing, should provide a more accurate representation of Frep/Tep binding interactions with the unaltered sporocyst surface.

2\) Biomphalysin, a pore-forming protein, is speculated as the mechanism responsible for plasma-mediated killing of sporocysts in vitro (Figure 4A). However, an alternative mechanism may be the presence of ROS (e.g., H~2~O~2~) naturally occurring in the plasma of BS-90 compared to M-line snails. To resolve this question, an experiment in which a ROS scavenger enzyme (e.g., catalase) is added to BS-90 plasma (and M-line plasma treated Frep/Tep) prior to sporocyst exposure in the CMC assay could be performed to eliminate an ROS-mediated mechanism.

3\) \"These pull-down results\" Also with interaction taking place without involvement of parasite products, is this the same for BS90 and M snails? How is this regulated in absence of pathogen to avoid aspecific continuous immune activation? Does FREP3 transport TEP to recognized parasite antigens, resulting in activation of TEP to facilitate downstream activation?
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Author response

> Essential revisions:
>
> 1\) Physical evidence that rFrep3 alone, but not rFrep2 or rTep1 alone, can bind to sporocysts is provided by ICC using fixed parasites. Assuming, as stated, that recomb. proteins bind to the outer tegumental of larvae, the localization pattern of Frep3 and Frep2/Tep1 binding do not appear to reflect such a surface binding pattern. This raises the question regarding the specificity of Frep2/3/Tep reactivity with the tegument of living sporocysts, which is at the center of this paper. Performing similar ICC experiments, initially treating live sporocysts to recombinant proteins (suggest shorter exposure times of 4-6 hrs), washing and then fixing, should provide a more accurate representation of Frep/Tep binding interactions with the unaltered sporocyst surface.

Thank you for the advice. Initially, we did not use confocal microscopy to evaluate tegumental binding. In our revised submission, we confirm tegument binding by clearly demonstrating a ring of recognition around the sporocyst. We approached this study as suggested, incubating live sporocysts with r*Bg*FREP3, r*Bg*FREP2, r*Bg*FREP2+r*Bg*TEP1 and r*Bg*TEP1 along with controls. As is now indicated in the Materials and methods, live primary sporocysts of *S. mansoni* were incubated with recombinant proteins at 26°C, then washed and fixed, and the subsequent steps were consistent with previous immunofluorescence staining experiments. We also replicated the method of our initial study, adding ther*Bg*FREP3+r*Bg*TEP1 treatment to further validate our pull-down results that suggest that FRE3 and TEP associate without immune stimulation, and assessed using a confocal microscope. These repeated studies also yielded clear surface binding. To replace the original images, we chose to use fixed sporocysts because the fluorescence intensity with fixed sporocysts was stronger than that with live sporocysts. We have included the images of the sporocysts that were incubated with the treatments while alive (as was suggested) as Figure 2---figure supplement 1.

> 2\) Biomphalysin, a pore-forming protein, is speculated as the mechanism responsible for plasma-mediated killing of sporocysts in vitro (Figure 4A). However, an alternative mechanism may be the presence of ROS (e.g., H~2~O~2~) naturally occurring in the plasma of BS-90 compared to M-line snails. To resolve this question, an experiment in which a ROS scavenger enzyme (e.g., catalase) is added to BS-90 plasma (and M-line plasma treated Frep/Tep) prior to sporocyst exposure in the CMC assay could be performed to eliminate an ROS-mediated mechanism.

We hadn't considered the possibility that BS-90 plasma may contain naturally-occurring ROS that was underpinning plasma-mediated killing. We undertook the recommended study to utilize a ROS scavenger specific to H~2~O~2~, added in advance to the BS-90 plasma. A ROS scavenger (catalase) was pre-incubated with cell-free BS-90 plasma and then the rest of the study was performed following the previously established method. With the exclusion of H~2~O~2~, BS-90 plasma was still able to kill *S. mansoni* sporocysts, thereby strengthening the likelihood of a non-ROS mediated mechanism by which humoral killing is mediated. The new results are presented in a revised Figure 4---figure supplement 1B.

> 3\) \"These pull-down results\" Also with interaction taking place without involvement of parasite products, is this the same for BS90 and M snails? How is this regulated in absence of pathogen to avoid aspecific continuous immune activation? Does FREP3 transport TEP to recognized parasite antigens, resulting in activation of TEP to facilitate downstream activation?

Regarding the r*Bg*FREP3 pull-down results, we identified *Bg*TEP1 in both BS-90 and M-line snails without the involvement of parasite products. Unfortunately, we do not know whether these interactions differ regarding their frequency within the different strains. Given that we have found *Bg*TEP1 levels to be similar between strains (Figure 1---figure supplement 3), the noticeable difference in *Bg*FREP3 levels, as evidenced by our Western Blots of snail plasma (Figure 1B), may in fact result in higher circulating levels of a *Bg*TEP/*Bg*FREP3 complex.

The reviewers raise an excellent point in questioning the mechanism of *Bg*TEP1 activation. Although *Bg*FREP3 appears to interact with *Bg*TEP1 in the plasma of both snail strains, as is demonstrated by the r*Bg*FREP3 pull-down results, we also show that r*Bg*FREP3 specifically interacted with *Bg*FREP2 and other versions of r*Bg*FREP3 only in BS-90 snail plasma. These differing results between strains suggests that specific immune complexes that associate with *Bg*TEP1 may be differentially activated and/or regulated depending on the specific *Bg*FREPs present. To date, we are not sure of the exact mechanism by which *Bg*TEP1 is activated, nor do we know how this activation is regulated in the absence of pathogen. In pursuit of a resolution to this query, we hypothesized that *Bg*TEP1 may operate in a similar manner to TEP1 of the *Anopheles gambiae*, in which a pair of Leucine-rich repeat containing molecules stabilize *Ag*TEP, prior to its binding to the surface of *Plasmodium* ookinetes (Fraiture et al., 2009). We thought that *Bg*FREP3 may function analogously to the LRR molecules LRIM1 and APLC, serving to stabilize *Bg*TEP1, while also guiding it to specific targets recognized by the *Bg*FREP on the parasite surface. Further protein pull-down investigations with a focus on determining whether *Bg*TEP1 cleavage products were observed reflected our past results, suggesting that *Bg*FREP3 interacts with a full-length form of *Bg*TEP1. This contrasts the observations from the *Anopheles* model and also those of Mone et al. which suggest that the C-terminal portion of *Bg*TEP1 associates with *S. mansoni* polymorphic mucins (*Sm*PoMucs). This suggests that once brought in association with the parasite, *Bg*TEP1 becomes cleaved/activated, but that activation (via cleavage into the N and C-terminal domains) does not occur without some pathogen-related stimulation. We have added clarification of this in the text of our Discussion.
